UiPath (NYSE:PATH) Given New $30.00 Price Target at Bank of America

UiPath (NYSE:PATH) had its target price lifted by Bank of America from $26.00 to $30.00 in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the healthcare company’s stock.

PATH has been the topic of several other research reports. JPMorgan Chase & Co. upgraded UiPath from a neutral rating to an overweight rating and upped their price objective for the company from $22.00 to $28.00 in a research note on Thursday. Barclays increased their price target on UiPath from $23.00 to $25.00 and gave the stock an equal weight rating in a research report on Friday. Wells Fargo & Company raised their price objective on UiPath from $24.00 to $25.00 and gave the company an equal weight rating in a report on Thursday. Canaccord Genuity Group raised their target price on UiPath from $27.00 to $30.00 and gave the stock a buy rating in a research report on Friday. Finally, Evercore ISI boosted their target price on UiPath from $24.00 to $27.00 and gave the company an in-line rating in a research report on Thursday. Nine research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of Hold and a consensus price target of $27.13.

UiPath Trading Up 1.4 %

NYSE:PATH traded up $0.32 on Thursday, hitting $23.07. The company’s stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. The stock has a fifty day moving average of $23.52 and a two-hundred day moving average of $20.70. The firm has a market capitalization of $13.06 billion, a P/E ratio of -135.46 and a beta of 0.97. UiPath has a one year low of $12.38 and a one year high of $27.87.

Insider Buying and Selling

In other UiPath news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares of the company’s stock, valued at approximately $9,928,144.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other UiPath news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares of the company’s stock, valued at approximately $9,928,144.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ashim Gupta sold 16,000 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $22.47, for a total transaction of $359,520.00. Following the sale, the chief financial officer now directly owns 103,505 shares in the company, valued at approximately $2,325,757.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 411,000 shares of company stock valued at $9,418,670. 31.03% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PATH. Mark Sheptoff Financial Planning LLC purchased a new stake in UiPath during the fourth quarter valued at about $25,000. HighMark Wealth Management LLC purchased a new stake in UiPath during the fourth quarter valued at about $27,000. Tyler Stone Wealth Management purchased a new stake in shares of UiPath during the second quarter worth about $28,000. Cypress Capital Management LLC WY purchased a new stake in shares of UiPath during the fourth quarter worth about $29,000. Finally, Fifth Third Bancorp boosted its holdings in shares of UiPath by 2,005.3% during the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock worth $34,000 after purchasing an additional 1,905 shares during the period. 59.04% of the stock is currently owned by hedge funds and other institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.